<DOC>
	<DOCNO>NCT01070927</DOCNO>
	<brief_summary>This study evaluate anti-tumour activity , safety tolerability RO4929097 monotherapy patient recurrent refractory non-small cell lung cancer . Patients receive oral dos RO4929097 80mg ( cohort 1 ) recommend Phase II dose ( cohort 2 ) 3 day 4 day schedule . Anticipated time study treatment disease progression unacceptable toxicity . Target sample size &lt; 50 .</brief_summary>
	<brief_title>An Exploratory Study RO4929097 Patients With Recurrent Refractory Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>adult patient , &gt; /= 18 year age stage IIIB/IV recurrent refractory nonsmall cell lung cancer 2 line prior therapy metastatic setting ( first line : platinum contain regimen bevacizumab ; second line : EGFRtargeted therapy ) ECOG performance status 02 adequate liver , renal bone marrow function prior chemotherapy radiotherapy &lt; /= 4 week first dose study drug history malignancy within past 2 year , except basal cell skin carcinoma situ cervical carcinoma history CNS metastases leptomeningeal metastasis , except clinically stable disease serious cardiovascular illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>